Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
RUKOBIA (ViiV Healthcare Pty Ltd)
Product name
RUKOBIA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
191 (255 working days)
Active ingredients
fostemsavir trometamol
Registration type
NCE/NBE
Indication
RUKOBIA (extended release tablet) is indicated in combination with other antiretroviral agents for the treatment of heavily treatment-experienced adults with multidrug-resistant human immunodeficiency virus-1 (HIV-1) infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen due to resistance, intolerance or safety considerations (see Section 5.1 PHARMACODYNAMIC PROPERTIES, Clinical Trials).